Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs KeyCorp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while KeyCorp trades at $19.97 (market cap $21.45B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 4.08% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and KeyCorp for 66 Days on average.
| HALO | KEY | |
|---|---|---|
Market Cap | $12.58B | $21.45B |
Volume | 2,179,278 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $115.22 | $23.99 |
52-Week Low | $61.63 | $16.78 |
Typical Hold Time | 1 Days | 66 Days |
Enterprise Value | $14.49B | $34.63B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KeyCorp (KEY) trades at $20.10, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments in wealth and retail banking.
The outlook is supported by analyst consensus with a $25.00 price target and 60.79% buy ratings, though risks include volatile cash flows and competitive pressures. Revenue growth momentum and aggressive share buybacks provide upside potential, but investors should weigh the frozen dividend against peers and monitor interest rate impacts on net interest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
